Morgan Stanley lowered the firm’s price target on Regeneron to $880 from $883 and keeps an Overweight rating on the shares. The firm issued its biotechnology Q1 sector preview, stating that broadly for the group it does not "expect many surprises" given recently issued guidance. The firm sees investor focus being mainly on Q2 catalysts in the space.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Regeneron Announces Investor Conference Presentations
- Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
- Capital One remains bullish on RPT193 as Rapt initiates Phase 2a Asthma study
- Regeneron price target raised to $950 from $900 at JPMorgan
- Regeneron price target raised to $940 from $925 at Jefferies
